European Society for Medical Oncology (ESMO)

The European Society for Medical Oncology (ESMO) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.
Psychological Support vs Standard of Care Following Chemotherapy for Ovarian Cancer
ESMO 2018
Patients receiving psychological support in the OVPSYCH2 randomized study showed reduced fear of progression compared with those without support. Read More ›
Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab vs Carboplatin/Gemcitabine/Bevacizumab in Patients with Recurrent Ovarian Cancer
ESMO 2018
The novel combination of carboplatin, pegylated liposomal doxorubicin, and bevacizumab has a promising safety and efficacy profile. Read More ›
Phase 3 Trial of Lurbinectedin vs Pegylated Liposomal Doxorubicin or Topotecan in Platinum-Resistant Ovarian Cancer Patients
ESMO 2018
Promising safety results from the CORAIL trial suggest a place for lurbinectedin in treating platinum-resistant ovarian cancer. Read More ›
Effect of Prior Chemotherapy Regimens on Rucaparib Treatment in Platinum-Sensitive Recurrent Ovarian Carcinoma
ESMO 2018
Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens. Read More ›
Long-Term Tolerability of Olaparib Tablets as Maintenance Therapy for Platinum-Sensitive Relapsed Ovarian Cancer
ESMO 2018
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation. Read More ›
Olaparib Maintenance Therapy in Patients with Platinum-Sensitive Relapsed Ovarian Cancer and Stable Disease
ESMO 2018
Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies. Read More ›
A Phase 2 Study of Durvalumab, a PD-L1 Inhibitor, and Olaparib in Recurrent Ovarian Cancer
ESMO 2018
Results suggest that the combination of durvalumab and olaparib was well-tolerated and had clinical activity in heavily pretreated, BRCA-wildtype ovarian cancer patients. Read More ›
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
ESMO 2018
Analysis of high-grade serous ovarian cancers suggests that BRCA1/2-driven cancers have a more favorable mode of relapse than sporadic cancers. Read More ›
Meta-Analysis of PARP-Inhibitor–Associated Gastrointestinal and Hepatic Toxicities
ESMO 2018
Early intervention and supportive care for gastrointestinal and hepatic toxicities should be considered for patients receiving PARP inhibitors. Read More ›
A Phase 1/2 Study of Chemo-Immunotherapy with Durvalumab and Pegylated Liposomal Doxorubicin (PLD) in Platinum-Resistant Recurrent Ovarian Cancer
ESMO 2018
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer. Read More ›

Page 4 of 9

© Amplity Health. All Rights Reserved. Privacy Policy